

---

## Medical Policy



Nonprofit corporations and independent licensees  
of the Blue Cross and Blue Shield Association

**Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and is therefore subject to change.**

---

**\*Current Policy Effective Date: 5/1/24**  
(See policy history boxes for previous effective dates)

### **Title: Genetic Testing for Cystic Fibrosis**

---

#### **Description/Background**

Cystic fibrosis (CF) is a multisystem genetic disease that affects the body's ability to move salt (chloride) and water in and out of cells. This causes tenacious mucus in the lungs, mucus plugs in the pancreas, and characteristically high sweat chloride levels. Symptoms vary and include very salty-tasting skin, persistent coughing, frequent lung infections, wheezing, shortness of breath, poor growth or weight gain in spite of good appetite, frequent greasy and/or bulky stools, difficulty with bowel movements and male infertility. Extensive lung damage and malnutrition can occur as a result.

There is no known cure for this progressive illness, but health problems can be managed. Treatment revolves around keeping the airway clear and maintaining adequate nutrition.

CF is an inherited autosomal recessive disorder. The CF transmembrane conductance regulator (*CFTR*) gene, which is mapped to chromosome 7, is responsible for making the protein that helps to move salt and water out of the cells. An individual must inherit 2 non-functioning copies of the *CFTR* gene, 1 from each parent, to have CF. If only 1 copy of the gene pair is mutated, the individual is a CF carrier. Carriers do not have the disease but can pass the defective copy of the mutated gene to their children. Approximately 1 in 35 Americans is a carrier, which means there are more than 10 million Americans who are asymptomatic carriers and many may not be aware of their ability to pass along the gene or the disease.

Statistics show that the chances of being a carrier of a *CFTR* mutation in the U.S. are as follows:

- 1 in 29 Caucasian-Americans
- 1 in 46 Hispanic-Americans
- 1 in 65 African-Americans
- 1 in 90 Asian-Americans

When both parents carry the mutated gene:

- 1 in 4 children (25%) will have CF
- 1 in 2 children (50%) will be a carrier, but will not have CF
- 1 in 4 children (25%) will not be a carrier or have CF.

Genetic carrier testing for the *CFTR* gene is performed to predict the risk of disease, to identify carriers and to formulate prenatal diagnosis/prognosis.

The U.S. Food and Drug Administration (FDA) has issued recommendations and guidance on pharmacogenetic tests and genetic tests for heritable markers, as well as special controls guidance documents for some specific types of genetics tests, including *CFTR* gene mutation detection systems.

---

## Regulatory Status

The FDA (2023) expanded use of Kalydeco for the treatment of cystic fibrosis (CF) in patients aged 1 month - and older who have at least 1 mutation in the *CFTR* gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data. The list of cystic fibrosis transmembrane conductance regulator (*CFTR*) Gene Mutations that produce *CFTR* protein and are responsive to Kalydeco are as follows:

- |                |           |          |          |          |
|----------------|-----------|----------|----------|----------|
| • 711+3A→G     | • F311del | • I148T  | • R75Q   | • S589N  |
| • 2789+5G→A    | • F311L   | • I175V  | • R117C  | • S737F  |
| • 3272-26A→G   | • F508C   | • I807M  | • R117G  | • S945L  |
| • 3849+10kbC→T | • F1052V  | • I1027T | • R117H  | • S977F  |
| • A120T        | • F1074L  | • I1139V | • R117L  | • S1159F |
| • A234D        | • G178E   | • K1060T | • R117P  | • S1159P |
| • A349V        | • G178R   | • L206W  | • R170H  | • S1251N |
| • A455E        | • G194R   | • L320V  | • R347H  | • S1255P |
| • A1067T       | • G314E   | • L967S  | • R347L  | • T338I  |
| • D110E        | • G551D   | • L997F  | • R352Q  | • T1053I |
| • D110H        | • G551S   | • L1480P | • R553Q  | • V232D  |
| • D192G        | • G576A   | • M152V  | • R668C  | • V562I  |
| • D579G        | • G970D   | • M952I  | • R792G  | • V754M  |
| • D924N        | • G1069R  | • M952T  | • R933G  | • V1293G |
| • D1152H       | • G1244E  | • P67L   | • R1070Q | • W1282R |
| • D1270N       | • G1249R  | • Q237E  | • R1070W | • Y1014C |
| • E56K         | • G1349D  | • Q237H  | • R1162L | • Y1032C |
| • E193K        | • H939R   | • Q359R  | • R1283M |          |
| • E822K        | • H1375P  | • Q1291R | • S549N  |          |
| • E831X        | • F1052V  | • R74W   | • S549R  |          |

Orkambi® (lumacaftor/ivacaftor) received FDA approval (2023) for the treatment of cystic fibrosis (CF) in patients aged 1 year and older who are homozygous for the *F508del* mutation in the *CFTR* gene.

Symdeko (tezacaftor/ivacaftor) received FDA approval (2023) for treatment of pediatric patients ages 6 years and older who are homozygous for the *F508del* mutation or who have at

least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.

Trikafta™ (elexacaftor/ivacaftor/tezacaftor) received expanded FDA approval (2023) for the treatment of cystic fibrosis in patients aged 2 years and older who have at least 1 copy of the *F508del* mutation in the *CFTR* gene **OR** a mutation in the *CFTR* gene that is responsive to Trikafta based on in vitro data.

---

## Medical Policy Statement

The safety and effectiveness of genetic testing for cystic fibrosis have been established. Genetic testing may be considered a useful diagnostic tool when indicated and should be performed in conjunction with appropriate pre-and post-test genetic counseling.

---

## Inclusionary and Exclusionary Guidelines

### **Inclusions:**

- Individuals planning pregnancy who have a family history of CF and the reproductive partners of those with CF.
- The prenatal population and those in the early stages of pregnancy when the test results will be used to make informed decisions regarding childbearing or a need for fetal diagnosis.
- Individuals, who have not undergone newborn screening, have an inconclusive sweat chloride test and there remains a suspicion of CF, when the results of the testing shall result in a definitive plan of patient management.
- Diagnostic testing in male infertility due to congenital bilateral absence of the vas deferens and carrier testing of their partners.
- Prenatal ultrasound findings that indicate an increased risk for CF (e.g. echogenic bowel or dilated loops of bowel)
- Gene mutation testing in patients with cystic fibrosis when used to guide medication regimens per FDA approved\* indications

Genetic testing should be performed in conjunction with appropriate pre-and post-test genetic counseling.

*\*See Regulatory Status section above for more information*

### **Exclusions:**

- Complete analysis of the *CFTR* gene by DNA sequencing is not appropriate for routine carrier screening

---

**CPT/HCPCS Level II Codes** *(Note: The inclusion of a code in this list is not a guarantee of coverage. Please refer to the medical policy statement to determine the status of a given procedure.)*

**Established codes:**

81220            81221            81222            81223            81224            88299

**Other codes (investigational, not medically necessary, etc.):**

N/A

*Note: The above code(s) may not be covered by all contracts or certificates. Please consult customer or provider inquiry resources at BCBSM or BCN to verify coverage.*

---

**Rationale**

According to the Cystic Fibrosis Foundation Patient Registry, there are more than 2,000 known mutations of the *CFTR* gene. Somewhere in the proximity of 40,000 people in the United States and 105,000 people across 94 countries are living with CF. Approximately 1,000 new cases are diagnosed each year. CF is 1 of the most common genetic diseases in Caucasians, with an incidence of about 1 in 2,500 to 3,500 White American live births. Hispanics have a 1 in 4,000-10,000 incidence. CF occurs in African Americans in approximately 1 in 17,000 births and 1 in 31,000 Asian Americans. CF occurs equally in men and women.

In 2010 it became mandatory for all newborns to be screened, via heel prick, for CF. Nearly two-thirds of individuals are diagnosed through newborn screening, 75% of individuals are diagnosed before the age of 2.

Individuals with CF experience a wide variety of medical conditions that affect the pulmonary, endocrine, gastrointestinal, pancreatic, biliary, and reproductive systems. Severity varies from person to person. Some have relatively mild disease and presentation occurs during adolescence and young adulthood. Others have severe pulmonary and gastrointestinal issues which lead to short life spans. Many times early death is related to pulmonary complications. According to an editorial posted in *Respiratory Medicine* (2022), in the last 30 years, life expectancy has increased from age 30 (1990) to age 50 (2022). The biggest improvements in outcomes for people with cystic fibrosis have been achieved through the use of cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The most recent and highly effective of these is triple therapy (elexacaftor plus tezacaftor plus ivacaftor [ETI]), which has shown unparalleled improvements in lung function and respiratory symptoms and reductions in pulmonary exacerbations. CFTR modulator therapy is potentially suitable for the roughly 90% of people with CF who are homozygous or heterozygous for F508del-CFTR; for the remaining 10% of patients with nonsense and missense mutations and other rare splicing defects, insertions, and deletions, innovative new treatments are vital. Research continues to look for anti-infective and anti-inflammatory treatments, as well as targeted treatments that can increase or repair CFTR function. Investigation continues for ways to restore CFTR function, including theratyping to find new mutations for CFTR modulators, readthrough agents for nonsense mutations, and allele-specific oligonucleotide therapy for splicing mutations. Despite advances in treatment, there is currently no cure for CF. Ninety percent of persons with CF die

from pulmonary complications. Major goals of traditional treatment of CF are to improve pulmonary, gastrointestinal and pancreatic outcomes.

Scotet et al (2020) reviewed the changes in the incidence and survival of CF and assessed the impact of the discovery of the responsible gene (the *CFTR* gene) on these changes. Authors concluded that significant advances in the management of cystic fibrosis in recent decades have dramatically changed the epidemiology and prognosis of this serious disease, which is no longer an exclusively pediatric disease. The incidence of CF appears to be decreasing in most countries and patient survival, which can be monitored by various indicators, has improved substantially, with an estimated median age of survival of approximately 50 years today. Cloning of the *CFTR* gene 30 years ago and efforts to identify its many mutations have greatly improved the management of CF. Implementation of genetic screening policies has enabled earlier diagnosis (via newborn screening), in addition to prevention within families or in the general population in some areas (via prenatal diagnosis, family testing or population carrier screening). In the past decade, in-depth knowledge of the molecular bases of CF has also enabled the emergence of *CFTR* modulator therapies which have led to major clinical advances in the treatment of CF. All of these phenomena have contributed to changing the face of CF. The advent of targeted therapies has paved the way for precision medicine and is expected to further improve survival in the coming years.

### **Cystic Fibrosis and Fetal Echogenic Bowel**

Cystic fibrosis is associated with a condition known as fetal echogenic bowel, which refers to increased echogenicity or brightness of the fetal bowel noted on ultrasound examination. Echogenic bowel has been reported to be found in 50% to 78% of fetuses affected with CF. Intestinal echogenicity was initially described as a normal variant, but it has recently been associated with various fetal abnormalities, including CF. Ultrasound detection of fetal echogenic bowel is associated with an increased risk of CF in pregnancies otherwise at low risk for this disease.

In a 2002 study, Scotet et al reviewed prenatal testing (in Brittany, France, an area with 1 of the highest incidences of CF in the world) for CF in pregnancies which showed an echogenic bowel. Over a 10 year period (1991-2000), 346,554 pregnancies, which did not end with a spontaneous abortion, had an ultrasound examination. Echogenic bowel was diagnosed during the second trimester in 142 cases, which were referred for a prenatal test for CF. Of the 142 cases, 14 fetuses were identified as carrying 2 *CFTR* mutations. This implies an incidence of CF in this population of approximately 1 in 10 (9.9%). The authors concluded that these results confirm that the ultrasound detection of fetal echogenic bowel is associated with an increased risk of CF in pregnancies otherwise at low risk.

Similarly, De Oronzo (2011) reported that in prospective evaluations of pregnancies at risk for CF, hyperechogenic bowel has been documented in up to 60% of affected fetuses. The report notes that “the association of echogenic bowel with fetuses affected with CF is thought to be caused by changes in the consistency of meconium in the small intestine as a result of abnormalities in pancreatic enzyme secretion. This can result in detectable sonographic findings, such as diffuse echogenic bowel, focal echogenic bowel with calcifications, a hyperechoic mass, or bowel dilation.” Additionally, “CF has been reported to affect 0.8% to 13.3% of fetuses with echogenic bowel, markedly higher than the rate of CF expected in a white population in which the carrier frequency is 1 in 25.”

### **Cystic Fibrosis and Male Infertility**

In addition to the aforementioned complications of CF, male fertility is significantly reduced with CF. The condition known as congenital bilateral absence of the vas deferens (CBAVD) exists in 75-80% of the patients with associated defects in the *CFTR* gene, and 97-98% of males with CF are infertile due to CBAVD and resultant obstructive azoospermia. Males with CBAVD can have *CFTR* gene mutations, but they may have no other manifestations of CF.

Tomaiuolo et al (2011) evaluated the link between *CFTR* mutations and infertility by sequencing the *CFTR* gene in 294 subjects (190 males) affected by infertility. As a control group, they studied 1000 (353 males) unrelated, unselected subjects from the general population. The frequency of *CFTR* mutations was significantly higher in obstructive and secretory azoospermic patients than in the general population. Some patients, primarily those with CBAVD, were compound heterozygous for 2 mutations. The researchers concluded that “all subjects affected by obstructive or secretory azoospermia should undergo molecular analysis and counselling for CF. Molecular analysis seems to be less mandatory in other types of male/female infertility.” Furthermore, the researchers found that the *CFTR* TG12-T5-V470 variant haplotype was associated with both severe oligospermia and tubal infertility, implicating the *CFTR* protein in both spermatogenesis and tubal functionality.

In 2012, Chen et al reviewed a number of studies and clinical evidence over the past 2 decades which evaluate the roles of *CFTR* mutations and CBAVD as they relate to male infertility. The reviewers noted that the clinical evidence shows increased mutation frequency or reduced *CFTR* expression in men with CBAVD or sperm abnormalities, such as azoospermia, teratospermia and oligoasthenospermia. Evidence also reveals a critical role of *CFTR* in sperm capacitation by directly or indirectly mediating HCO<sub>3</sub> entry that is essential for capacitation. The authors concluded that *CFTR* is a key regulator of male fertility, a defect of which may result in different forms of male infertility other than CBAVD.

Asadi et al (2018) investigated the frequency of the most common mutations of the *CFTR* gene (*DF508*, *G542X*, *N1303K*, *G551D*, and *W1282X*) in a population of infertile men with nonobstructive azoospermia (NOA) and CBAVD. Blood samples were obtained from 50 NOA, 50 CBAVD, and 100 normal males (control). Genomic DNA was isolated from whole blood leukocytes, and the presence of common mutations of the *CFTR* gene was assessed by an amplification refractory mutation system-polymerase chain reaction (ARMS-PCR). Restriction fragment length polymorphism (PCR-RFLP) was also used to analyze IVS8-Tn polymorphism. It was found that 16%, 8%, and 8% of patients with CBAVD were heterozygote for *DF508*, *G542X*, and *N1303K*, respectively. The frequency of the 5T allele was 34% and higher than the normal group ( $p < 0.001$ ). None of the common *CFTR* gene mutations were detected in NOA patients, and no significant difference was found in the distribution of the 5T allele between the NOA patients and the control group (5 vs. 3  $p = 0.721$ ). The authors concluded that the *CFTR* gene mutations and IS8-Tn polymorphisms are correlated with CBAVD; however, extensive investigations to determine the exact relationship between the gene mutations and other forms of male infertility were recommended.

## Pharmacogenetics

Identification of the mutated *CFTR* gene allows for target therapy as follows:

- Kalydeco™ is an orally self-administered *CFTR* potentiator. It is a unique medication that improves CF symptoms by facilitating increased chloride transport by potentiating the channel-open probability of the *G551D-CFTR* protein. It is the first treatment for CF patients that targets the underlying cause of CF.

- Orkambi™ is a combination therapy of ivacaftor (Kalydeco) and lumacaftor (VX-809) for treatment of individuals aged 12 and older who have 2 copies of the *F508del* mutation in their *CFTR* gene. The *F508del* mutation causes an abnormal protein to be produced that disrupts water and chloride transport in the body.
  - Lumacaftor is a cystic fibrosis transmembrane conductance regulator (*CFTR*) corrector, which helps *CFTR* protein reach the cell surface.
  - Kalydeco (ivacaftor), known as a *CFTR* potentiator, keeps the *CFTR* protein channels on the cell surface open longer to increase the flow of salt and water into and out of the cell.
- If the patients genotype is unknown, an FDA cleared CF mutation test should be used to detect the presence of the *F508del* mutation on both alleles of the *CFTR* gene.

### Summary

Cystic fibrosis is a complex disease. Symptoms can vary significantly by type and severity (mild to severe) from 1 person to another. Some mutations have been associated with specific areas of the body including the lungs, pancreas, liver and other organs. Characterizing the gene mutation may help to identify which system is most likely to be affected and may assist in guiding appropriate treatment.

The severity of future symptoms cannot be fully predicted from an understanding of the specific gene mutation. However, screening can identify the presence of those mutations which are known to be associated with milder symptoms.

A family history of CF or CF carriers increases the chance of a person carrying a mutation that has the potential to be passed to their children. Carriers do not have symptoms, thus the *CFTR* mutation can be passed to offspring without anyone having the disease or a known family history. Unless a child is born with CF, many people who are carriers may not be aware of their ability to pass along the *CFTR* gene.

Genetic testing for cystic fibrosis plays a key role in allowing parents to make informed decisions regarding childbearing and guides health providers in determining effective treatment modalities. For childbearing, results of carrier testing provide the certainty of the predicted risk that offspring will be affected by a severe mutation for any of the disorders included in the panel. Such information can be used to make informed reproductive decisions such as preimplantation, genetic diagnosis, in vitro fertilization, not having a child, invasive prenatal testing, adoption, or pregnancy termination.

---

## Supplemental Information

### PRACTICE GUIDELINES AND POSITION STATEMENTS

#### American College of Obstetricians and Gynecologists Committee

The American College of Obstetricians and Gynecologists' Committee on Genetics (2017) updated current guidelines for cystic fibrosis screening practices. The committee made the following recommendations:

- Cystic fibrosis carrier screening should be offered to all women who are considering pregnancy or are currently pregnant.
- Complete analysis of the *CFTR* gene by DNA sequencing is not appropriate for routine carrier screening.
- For couples in which both partners are unaffected but 1 or both has a family history of CF, genetic counseling and medical record review should be performed to determine if *CFTR* mutation analysis in the affected family member is available.
- If a woman's reproductive partner has CF or apparently isolated congenital bilateral absence of the vas deferens, the couple should be provided follow-up genetic counseling by an obstetrician-gynecologist or other health care provider with expertise in genetics for mutation analysis and consultation

#### EU Project EuroGentest and the European Cystic Fibrosis Network

The EU project EuroGentest and the European Cystic Fibrosis Network (2009) issued recommendations and best practice guidelines for molecular genetic diagnosis of CF and *CFTR*-related disorders. Indications for *CFTR* testing were outlined:

- Diagnostic testing in typical CF presentation
- Diagnostic testing in atypical clinical presentation and/or borderline sweat test
- Diagnostic testing in male infertility with CBAVD
- Diagnostic testing in other *CFTR-RD* in adults
- Diagnostic testing in fetuses with bowel hyperechogenicity and/or loop dilatation
- Prenatal diagnosis
- CF carrier testing in individuals with a positive family history
- CF carrier screening in individuals without a family history
- CF carrier testing in infertile couples

#### National Society of Genetic Counselors

The National Society of Genetic Counselors (2013) issued practice guidelines for molecular testing for CF carrier status. Some of the recommendations are as follows:

- Carrier testing for CF should be offered to all women of reproductive age, regardless of ancestry; preferably preconceptionally. CF carrier testing should also be offered to any individual with a family history of CF and to partners of mutation carriers and people with CF.
- Pre-test risk assessment should include an estimate of CF carrier frequency based on the individual's family history, ethnic background, and the predicted residual risk to have a child with CF if the test is negative.
- Carrier testing panels should include the mutations recommended by the American College of Obstetricians and Gynecologists' and the American College of Medical Genetics. For individuals of non-Northern European descent, pan-ethnic panels that



include additional mutations more commonly identified in minority populations are appropriate to consider: Focus general population CF screening practices on identifying carriers of established disease-causing *CFTR* mutations.

- When both parents are known carriers for CF, available prenatal and pre-implantation diagnostic testing should be offered. Prenatal facilitation of a monitoring plan should begin for couples at risk or who continue a pregnancy known to have CF, and postnatal evaluation through sweat testing and state NBS programs, should be discussed.
- If a client is found to carry an *R117H* mutation, it is important to ensure the testing laboratory performs reflex testing for poly T status along with studies to determine the cis/trans orientation of the poly T alleles. In the absence of an *R117H* mutation, assessment of the intron 8 poly T or TG tracts is not recommended for routine CF carrier testing

### **National Institutes of Health**

The National Institutes of Health Consensus Development Program genetic testing recommendations for CF (1999) are as follows:

- Individuals with a family history of CF and the reproductive partners of those with CF should be offered genetic testing.
- CF genetic testing should be offered to the prenatal population and couples currently planning a pregnancy, particularly those in high-risk populations.
- CF testing for the general population is not advocated.

---

## **Government Regulations**

### **National:**

National Medicare does not have a policy specifically addressing genetic testing for CF. Medicare's indications for genetic testing are to rule out a constitutional or acquired chromosomal abnormality. Constitutional abnormalities refer to those present at birth, prenatally or postnatally. Acquired chromosome abnormalities refer to those that are typically acquired after birth by a subpopulation of cells that is involved in a premalignant or malignant condition. Medicare may review genetic testing for CF on a case-by-case basis.

### **Local:**

Local Coverage Determination: MoIDX: **Pharmacogenomics Testing**

(L38435) Original Effective Date: 7/26/20; Revision Effective Date: 8/24/23

PGx tests are indicated when medications are being considered for use (or already being administered) that are medically necessary, appropriate, and approved for use in the patient's condition and are known to have a gene(s)-drug interaction that has been demonstrated to be clinically actionable as defined by the FDA (PGx information required for safe drug administration) or Clinical Pharmacogenetic Implementation Consortium (CPIC) guidelines (category A and B).

The selection of the medications in question must be derived from clinical factors/necessity rather than from a PGx test. Once the putative therapeutic agents are selected, and those agents are known to have gene-drug interactions as identified above, then a PGx test may be considered reasonable and necessary when the result of that test is necessary for the physician's decision-making process regarding safely administering or dosing the drug.

PGx testing is not considered reasonable and necessary merely on the basis of a patient having a particular diagnosis. Unless the record reflects that the treating clinician has already considered non-genetic factors to make a preliminary drug selection, PGx testing is not considered reasonable and necessary.

Local Coverage Article: **Response to Comments: Molecular Pathology Procedure** (A55334) Original Effective Date: 12/01/16

Requests were received in support of coverage for CPT Codes 81220, 81221, 81222, 81223, 81224 (cystic fibrosis transmembrane conductance regulator) (e.g., cystic fibrosis) gene analysis, common variants (e.g. ACMG/ACOG guidelines). NGS agrees and will provide coverage for a beneficiary who has or may have cystic fibrosis to guide therapeutic decision-making.

Local Coverage Article: **Billing and Coding: MoIDX: Testing of Multiple Genes** (A57880); Effective date: 12/26/19; Revision date: 2/28/23

A panel of genes is a distinct procedural service from a series of individual genes. All services billed to Medicare must be reasonable and necessary. As such, if a provider or supplier submits a claim for a panel, then the patient's medical record must reflect that the panel was reasonable and necessary. Alternatively, if a provider or supplier bills for a number of individual genes, then the patient's medical record must reflect that each individual gene is reasonable and necessary.

When 2 or more codes are submitted for the same beneficiary on the same date of service, the claims processing system will reject every code submitted after the first service. However, if a lab runs more than 1 distinct procedural service on a single date of service, then the lab must use the 59 modifier with each additional service billed as an attestation that it is a distinct procedural service.

Local Coverage Article: **Billing and Coding: MoIDX: Pharmacogenomics Testing** (A58395); Effective 7/26/20; Revised 10/1/23

Only 1 test may be performed per date of service; the test should be the most likely to identify the necessary alleles/variants for the drug/drugs in question. This applies to both single gene tests and multigene panels. Multigene panels can be performed when (as defined in the policy):

- More than 1 gene is reasonable and necessary for the safe use of the drug being considered or in use; or
- More than 1 drug is in consideration or use that is associated with a gene-drug interaction

A multigene panel must include all relevant genes and variants for its intended use to be reasonable and necessary.

Gene/Test	CPT Code	Intended use for Drug	Trade Name	Brand Name
CFTR	81220	Cystic fibrosis	ivacaftor	Kalydeco

*(The above Medicare information is current as of the review date for this policy. However, the coverage issues and policies maintained by the Centers for Medicare & Medicare Services [CMS, formerly HCFA] are updated and/or revised periodically. Therefore, the most current CMS information may not be contained in this document. For the most current information, the reader should contact an official Medicare source.)*

---

## Related Policies

- Genetic Testing and Counseling
  - Genetic Testing - Carrier Screening for Genetic Diseases
  - Kalydeco™ (ivacaftor) (P&T Policy)
  - Orkambi™ (lumacaftor/ivacaftor) (P&T policy)
- 

## References

1. American College of Obstetricians and Gynecologists. (ACOG). Committee Opinion #691, Mar, 2017. "Carrier Screening for Genetic Conditions." Replaces #486, Apr 2011. Reaffirmed 2023. <https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/03/carrier-screening-for-genetic-conditions>. Accessed January 5, 2024.
2. Asadi, F. et al., "A survey of the common mutations and IVS8-Tn polymorphism of cystic fibrosis transmembrane conductance regulator gene in infertile men with nonobstructive azoospermia and CBAVD in Iranian population," Iran Biomed (2018). PMID 29986553
3. Centers for Disease Control and Prevention (CDC), National Office of Public Health Genomics, Cystic Fibrosis Clinical Validity, pp. 1-9.
4. Centers for Medicare & Medicaid Services. "Local Coverage Article: Billing and Coding: MoIDX: Testing of Multiple Genes." (A57880). 2023. <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=57880&ver=12&keyword=A57880&keywordType=all&areald=s27&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc=1>. Accessed January 5, 2024.
5. Centers for Medicare & Medicaid Services. "Local Coverage Article: Pharmacogenomics Testing." (A58395). 2023. <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=58395&ver=26&keyword=Pharmacogenomics%20Testing&keywordType=all&areald=s27&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc=1>. Accessed January 5, 2024.
6. Centers for Medicare & Medicaid Services. "Local Coverage Article: Response to Comments: Molecular Pathology Procedures." (A55334). 2016. <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=55334&ver=6&keyword=A55334&keywordType=all&areald=s27&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc=1>. Accessed January 5, 2024.
7. Centers for Medicare & Medicaid Services. "Local Coverage Determination: MoIDX: Pharmacogenomics Testing." L38435. 2023. <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38435&ver=10&keyword=L38435&keywordType=all&areald=s27&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc=1>. Accessed January 5, 2024.
8. Chan, H et al., "The cystic fibrosis transmembrane conductance regulator in reproductive health and disease," *J Physiol* 587.10 (2009) pp 2187–2195.
9. Chen, Hui et al., "Regulation of male fertility by CFTR and implications in male infertility," Human Reproduction Update, Vol.0, No.0, pp. 1–11, 2012.
10. Cystic Fibrosis Foundation. "About Cystic Fibrosis." n.d. <https://www.cff.org/intro-cf/about-cystic-fibrosis#:~:text=There%20are%20close%20to%2040%2C000%20children%20and,105%>

[2C000%20people%20have%20been%20diagnosed%20with%20CF](#). Accessed January 4, 2024.

11. Cystic Fibrosis Foundation, “Carrier Testing for CF.” n.d. <https://www.cff.org/intro-cf/carrier-testing-cystic-fibrosis>. Accessed January 4, 2024.
12. De Oronzo, MA, “Hyperechogenic fetal bowel: an ultrasonographic marker for adverse fetal and neonatal outcome?” *Journal of Prenatal Medicine*, 2011; 5 (1): 9-13.
13. Dequeker, Els et al., “Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders – updated European recommendations,” *European Journal of Human Genetics* (2009) 17, 51–65.
14. Federal Employee Program Administrative Manual Volume 1, 2005, Maternity Care, *Family Planning, and Infertility Services Benefits*, Chapter 5, Last Update: January 2005, pp. 5.
15. Gallati, Sabrina, “Cystic fibrosis transmembrane conductance regulator mutations in azoospermic and oligospermic men and their partners,” *Reproductive BioMedicine Online*, Vol. 19. No 5, 2009, 685–694.
16. HU Medical Review Board. “How Common is Cystic Fibrosis?” 2024. <https://cystic-fibrosis.com/statistics>. Accessed January 4, 2024.
17. Langfelder-Schwind, Elinor et al, “Molecular Testing for Cystic Fibrosis Carrier Status Practice Guidelines: Recommendations of the National Society of Genetic Counselors,” *Journal of Genetic Counseling*, 9/7/13.
18. National Institutes of Health Consensus Development Conference Statement (NIH), “Genetic Testing for Cystic Fibrosis, National Institutes of Health Consensus Development Conference Statement on genetic testing for cystic fibrosis.” *Arch Intern Med*.1999. Jul 26;159(14):1529-39. PMID: 10421275.
19. Respiratory Medicine. “Cystic Fibrosis treatment: Hope for all?” *The Lancet*. 2022;10(12):1099. <https://www.thelancet.com/action/showPdf?pii=S2213-2600%2822%2900447-7>. Accessed December 13, 2022.
20. Scotet, V et al., “Prenatal detection of cystic fibrosis by ultrasonography: a retrospective study of more than 346 000 pregnancies,” *J Med Genet*, 2002;39:443–448.
21. Scotet V, L'Hostis C, Férec C. “The Changing Epidemiology of Cystic Fibrosis: Incidence, Survival and Impact of the CFTR Gene Discovery.” *Genes (Basel)*. 2020 May 26;11(6):589. doi: 10.3390/genes11060589. PMID: 32466381; PMC ID: PMC7348877
22. Tomaiuolo, R. et al., “Enhanced frequency of *CFTR* gene variants in couples who are candidates for assisted reproductive technology treatment,” *Clinical Chemistry and Laboratory Medicine*, Volume 49, Issue 8, pp. 1289–1293, June 2011.
23. U.S. Food and Drug Administration (FDA). “Center for Devices and Radiological Health - Guidance for Industry and FDA Staff-Class II Special Controls Guidance document: Quality Control Material for Cystic Fibrosis Nucleic Acid Assays,” Document Issued on January 10, 2007; <http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm071456.pdf>. Accessed December 13, 2022.
24. United States Food & Drug Administration. “Highlights of prescribing information – Kalydeco.” August 2023. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/203188s040,207925s017lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203188s040,207925s017lbl.pdf). Accessed January 4, 2024.
25. United States Food & Drug Administration. “Highlights of Prescribing Information – Orkambi.” August 2023. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/206038s017,211358s005lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206038s017,211358s005lbl.pdf). Accessed January 4, 2024.

26. United States Food & Drug Administration. "Highlights of Prescribing information – Symdeko." August 2023.  
[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/210491s011lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210491s011lbl.pdf). Accessed January 4, 2023.
27. United States Food & Drug Administration. "Highlights of Prescribing information – Trikafta" August 2023.  
[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/212273s011,217660s002lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212273s011,217660s002lbl.pdf). Accessed January 4, 2023.
28. Watson, Michael S., et al., "Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetic mutation panel," September/October 2004, Vol. 6, No. 5.

*The articles reviewed in this research include those obtained in an Internet based literature search for relevant medical references through 1/5/24, the date the research was completed.*

**Joint BCBSM/BCN Medical Policy History**

<b>Policy Effective Date</b>	<b>BCBSM Signature Date</b>	<b>BCN Signature Date</b>	<b>Comments</b>
7/1/08	5/19/08	7/1/08	Joint policy established
7/1/09	4/21/09	6/14/09	Routine maintenance
5/1/11	2/15/11	3/3/11	Routine maintenance
7/1/12	4/10/12	5/18/12	Code update; replaced S3835 with 81220-81223; routine maintenance
3/1/14	12/10/13	1/6/14	Routine maintenance; added code 81224 and 88299; updated policy to reflect coverage for CFTR gene analysis for male infertility and fetal echogenic bowel.
5/1/15	2/17/15	2/27/15	Routine maintenance
5/1/16	2/16/16	2/16/16	Routine maintenance Updated criteria to include genetic testing to confirm specific mutations prior to treatment with Kalydeco and (FDA approval of) Orkambi.
5/1/17	2/21/17	2/21/17	Routine maintenance
5/1/18	2/20/18	2/20/18	Routine maintenance
5/1/19	2/19/19		Routine maintenance
5/1/20	2/18/20		Routine maintenance
5/1/21	2/16/21		Updated criteria to include additional mutations prior to treatment with Kalydeco; FDA approval of Symdeko and Triafta; and FDA approved age changes for Orkambi (2 to 12 y/o)
5/1/22	2/15/22		Updated FDA approval of Trikafta for ages 6 and older and to include a mutation in the CFTR gene that is responsive based on in vitro data
5/1/23	2/21/23		Routine maintenance (slp) Vendor Managed: N/A
5/1/24	2/20/24		Routine maintenance (slp) Vendor Managed: N/A LCDs updated

Next Review Date: 1<sup>st</sup> Qtr, 2025

**BLUE CARE NETWORK BENEFIT COVERAGE  
POLICY: GENETIC TESTING FOR CYSTIC FIBROSIS**

**I. Coverage Determination:**

<b>Commercial HMO (includes Self-Funded groups unless otherwise specified)</b>	Covered; criteria apply
<b>BCNA (Medicare Advantage)</b>	Refer to the Medicare information under the Government Regulations section of this policy.
<b>BCN65 (Medicare Complementary)</b>	Coinsurance covered if primary Medicare covers the service.

**II. Administrative Guidelines:**

- The member's contract must be active at the time the service is rendered.
- Coverage is based on each member's certificate and is not guaranteed. Please consult the individual member's certificate for details. Additional information regarding coverage or benefits may also be obtained through customer or provider inquiry services at BCN.
- The service must be authorized by the member's PCP except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Services must be performed by a BCN-contracted provider, if available, except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Payment is based on BCN payment rules, individual certificate and certificate riders.
- Appropriate copayments will apply. Refer to certificate and applicable riders for detailed information.
- CPT - HCPCS codes are used for descriptive purposes only and are not a guarantee